Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.
An experimental drug developed by Seattle Genetics Inc. and Astellas Pharma Inc. led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to presented data.
Johnson & Johnson wins U.S. FDA approval for bladder cancer drug
Advanced bladder cancer, Approvals, Biomarkers, Breakthrough Therapy Designation, FDA, FDA/Regulatory, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Genetic Mutations, New Drug Application (NDA), Pricing, Priority Review, Shares, Side EffectsJohnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration announced.
The first comprehensive study comparing the outcomes of robotic surgery to those of traditional open surgery in any organ found that the surgeries are equally effective in treating bladder cancer.
Projected blockbuster bio products with potential launches in 2016
Atopic Dermatitis, Bladder, Bladder Cancer, Clinical Trials, Immunotherapies, Issue Archives, June 2016, Launches, Multiple Sclerosis, PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Product Launches, Prostacyclin Receptor Agonists, Pulmonary Arterial Hypertension, R&D, Relapsing Multiple Sclerosis (RMS)Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread […]
